Twist Bioscience Corporation

NASDAQ:TWST

Medical - Diagnostics & Research

Healthcare
$116.35 +2.59%

+$2.15 today

Market cap
$7.66B
Beta
2.21
P/E (TTM)
-64.5
EPS (TTM)
-$1.32
52W Low $23.30High $88.46

Volume 2.23M

Average 1.53M

TWST Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Twist Bioscience CorporationNASDAQ: TWST

Depreciation & Amortization · Q4 FY2026 · quarter ended Sep 2026

Depreciation & amortization turns negative

Q4 FY2026 depreciation & amortization was -$19.39M, compared with $6M a year earlier. Trailing-twelve-month depreciation & amortization was $0.

Context

  • Depreciation & amortization amounted to 0.0% of revenue in FY2026, down 6.6 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2026 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly depreciation & amortization holds near -$19.39M or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$19.39M-386.0% QoQ
Last fiscal yearSep 2026
$0-100.0% YoY
LTMSep 2026
$0-100.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-422.9%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2026
0 USD
Year-over-year change
-100.0%

Depreciation & Amortization vs competitors

How TWST compares with its peers on the latest reported figures

  • TWST's LTM Sep 2026 depreciation & amortization of $0 is the lowest of the 2 companies compared; the peer median is $97.31M.
  • Its year-over-year change of -100.0% is the lowest of 2, against a peer median of -7.0%.
  • Depreciation & amortization amounts to 0.0% of revenue for TWST, versus a peer median of 12.4%.
TWST Competitors Peer median
Depreciation & Amortization for TWST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RGENRepligen CorporationLTM Jun 2026$97.31M -7.0%+19.4%12.4%
TWSTTwist Bioscience CorporationLTM Sep 2026$0 -100.0%—0.0%
Peer median (excluding TWST) $97.31M-7.0%+19.4%12.4%

Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue203.57M245.11M312.97M376.57M459.43M
Cost of Revenue119.33M155.38M179.63M185.57M218.63M
Gross Profit84.24M89.73M133.35M191M240.8M
Gross Margin41.4%36.6%42.6%50.7%52.4%
Research & Development120.31M106.89M90.85M80.29M71.84M
Selling, General & Admin212.95M189.74M218.4M246.98M301.22M
Operating Expenses319.01M306.89M354.18M327.26M380.26M
Depreciation & Amortization16.51M29.31M31.43M24.85M0
EBITDA(211.68M)(174.15M)(176.71M)(52.1M)(129.8M)
EBITDA Margin-104.0%-71.1%-56.5%-13.8%-28.3%
Operating Income(234.78M)(217.16M)(220.83M)(136.26M)(139.46M)
Operating Margin-115.3%-88.6%-70.6%-36.2%-30.4%
Interest Income3.06M14.37M15.34M11.36M8.8M
Interest Expense80K5K29K00
Other Income / Expenses6.5M13.69M12.67M59.31M8.85M
Income Before Tax(228.27M)(203.47M)(208.17M)(76.95M)(130.61M)
Pre-Tax Margin-112.1%-83.0%-66.5%-20.4%-28.4%
Income Tax Expense(10.41M)1.15M560K719K(406K)
Net Income(217.86M)(204.62M)(208.73M)(77.67M)(130.2M)
Net Margin-107.0%-83.5%-66.7%-20.6%-28.3%
EPS (Basic)(4.04)(3.60)(3.60)(1.30)(2.08)
EPS (Diluted)(4.04)(3.60)(3.60)(1.30)(2.08)
Weighted Avg Shares53.89M56.89M58.02M59.81M62.62M
Weighted Avg Shares (Diluted)53.89M56.89M58.02M59.81M62.62M

Twist Bioscience Corporation

NASDAQ:TWST

Intrinsic Alpha fair value

Locked

Current Price

$116.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.